Cover Image
市場調查報告書

葡萄薄膜炎 : 開發平台分析

Uveitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 219766
出版日期 內容資訊 英文 194 Pages
訂單完成後即時交付
價格
Back to Top
葡萄薄膜炎 : 開發平台分析 Uveitis - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 194 Pages
簡介

所謂葡萄膜炎是指葡萄膜(眼球中間層──虹膜·睫狀體·脈胳膜)的發炎和刺激作用。有可能單眼或雙眼同時發病。發病的原因有自體免疫障礙(類風濕性關節炎,強直性脊椎症及其他)和感染疾病,以及曝露在毒素下等。主要的症狀有視力降低、飛蚊症、眼球痛、充血、畏光等。容易罹病的危險因子有受感染或自體免疫/發炎性疾病、眼睛外傷病史等。主要的治療方法有類固醇系眼藥和抗發炎劑,抗生素,抗病毒藥物等。

本報告提供全球各國治療葡萄薄膜炎用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

葡萄薄膜炎概要

治療藥的開發

  • 葡萄薄膜炎開發中產品:概要
  • 葡萄薄膜炎開發中產品:比較分析

各企業開發中的葡萄薄膜炎治療藥

大學/研究機關研究中的葡萄薄膜炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

葡萄薄膜炎治療藥:開發中的產品的一覽(各企業)

葡萄薄膜炎治療藥:研究中的產品的一覽(大學/研究機關別)

葡萄薄膜炎治療藥的開發企業

  • 2-BBB Medicines BV
  • AbbVie Inc.
  • Aciont Inc.
  • Aldeyra Therapeutics, Inc.
  • Apitope International NV
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • Clearside BioMedical, Inc.
  • Effimune SAS
  • Endocyte, Inc.
  • Enzo Biochem, Inc.
  • EyeGate Pharmaceuticals, Inc.
  • HanAll Biopharma Co., Ltd.
  • Icon Bioscience, Inc.
  • IMMD Inc.
  • Innomedica Ltd.
  • Johnson & Johnson
  • Kineta, Inc.
  • Neuroptis Biotech
  • Novartis AG
  • Ocata Therapeutics, Inc.
  • OncoNOx ApS
  • Palatin Technologies, Inc.
  • Panoptes Pharma Ges.m.b.H.
  • Pfizer Inc.
  • pSivida Corp.
  • Regeneron Pharmaceuticals, Inc.
  • 參天製藥
  • SynDevRx, Inc.
  • ThromboGenics NV
  • TxCell SA
  • Virogenomics, Inc.
  • XOMA Corporation

葡萄薄膜炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • 2B3-201
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • abataseputo
  • Adalimumab
  • ATXUV-1
  • ATXUV-2
  • B27-PD
  • serekokishibu
  • Col-Treg
  • Cyclosporine SR
  • Cytectin
  • dalazatide
  • dexamethasone acetate
  • dexamethasone acetate
  • 地塞米松磷酸鈉
  • 慢性葡萄薄膜炎治療藥
  • 免疫學·眼科學·感染疾病·代謝障礙·呼吸系統疾病醛醣還原酵素抑制劑
  • EC-1496
  • EC-1669
  • Fluocinolone Acetonide SR
  • FR-104
  • gevokizumab
  • HL-036
  • IMD-0354
  • INV-17
  • LFG-316
  • LME-636
  • rodamin
  • methotrexate
  • NOP-3
  • NS-2
  • 葡萄膜炎IL-10活躍寡核甘酸
  • OX-1001
  • PA-2612
  • 葡萄膜炎TCR調整用胜肽
  • piclidenoson
  • PL-8177
  • plastoquinone decyl triphenylphosphonium bromide
  • PP-001
  • PPL-003
  • 葡萄膜炎基因改造型酵素
  • sarilumab
  • sirolimus
  • 葡萄膜炎 5-lipoxygenase阻礙小分子
  • 自體免疫疾病幹細胞療法
  • TG-931
  • TOP-1288
  • Triamcinolone acetonide
  • Triamcinolone acetonide

葡萄薄膜炎治療藥:開發中產品的最新趨勢

葡萄薄膜炎治療藥:暫停開發的產品

葡萄薄膜炎治療藥:中止開發的產品

葡萄薄膜炎相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8544IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H2 2016, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 8, 2, 1, 26 and 6 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Uveitis.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Uveitis Overview
  • Therapeutics Development
    • Pipeline Products for Uveitis - Overview
    • Pipeline Products for Uveitis - Comparative Analysis
  • Uveitis - Therapeutics under Development by Companies
  • Uveitis - Therapeutics under Investigation by Universities/Institutes
  • Uveitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Uveitis - Products under Development by Companies
  • Uveitis - Products under Investigation by Universities/Institutes
  • Uveitis - Companies Involved in Therapeutics Development
    • 2-BBB Medicines BV
    • AbbVie Inc
    • Aciont Inc.
    • Aldeyra Therapeutics Inc
    • Apitope International NV
    • Astellas Pharma Inc.
    • Bionomics Limited
    • Bristol-Myers Squibb Company
    • Can-Fite BioPharma Ltd.
    • Clearside BioMedical, Inc.
    • Endocyte, Inc.
    • Enzo Biochem, Inc.
    • EyeGate Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • HanAll Biopharma Co., Ltd.
    • Icon Bioscience, Inc.
    • KPI Therapeutics, Inc.
    • Midatech Pharma Plc
    • Mitotech S.A.
    • Neuroptis Biotech
    • Novartis AG
    • Oculis ehf
    • OncoNOx ApS
    • OSE Immunotherapeutics
    • Palatin Technologies, Inc.
    • Panoptes Pharma Ges.m.b.H.
    • Pfizer Inc.
    • Precision Ocular Ltd
    • pSivida Corp.
    • Regeneron Pharmaceuticals Inc
    • Santen Pharmaceutical Co., Ltd.
    • SynDevRx, Inc.
    • TopiVert Ltd
    • TxCell SA
  • Uveitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 2-B3201 - Drug Profile
    • abatacept - Drug Profile
    • adalimumab - Drug Profile
    • ANV-103 - Drug Profile
    • ATXUV-1 - Drug Profile
    • ATXUV-2 - Drug Profile
    • B27-PD - Drug Profile
    • BNC-164 - Drug Profile
    • celecoxib - Drug Profile
    • Col-Treg - Drug Profile
    • CVX-001 - Drug Profile
    • cyclosporine SR - Drug Profile
    • dalazatide - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone sodium phosphate - Drug Profile
    • Drug for Chronic Uveitis - Drug Profile
    • Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile
    • EBI-031 - Drug Profile
    • EC-1669 - Drug Profile
    • EYS-606 - Drug Profile
    • fluocinolone acetonide SR - Drug Profile
    • FR-104 - Drug Profile
    • Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis - Drug Profile
    • HL-036 - Drug Profile
    • HO-10 - Drug Profile
    • INV-17 - Drug Profile
    • IVMED-10 - Drug Profile
    • IVMED-20 - Drug Profile
    • KPI-190 - Drug Profile
    • LME-636 - Drug Profile
    • lodamin - Drug Profile
    • methotrexate - Drug Profile
    • NOP-3 - Drug Profile
    • NS-2 - Drug Profile
    • OX-1001 - Drug Profile
    • piclidenoson - Drug Profile
    • PL-8177 - Drug Profile
    • plastoquinone decyl triphenylphosphonium bromide - Drug Profile
    • PP-001 - Drug Profile
    • PPL-003 - Drug Profile
    • Recombinant Enzymes for Uveitis - Drug Profile
    • sarilumab - Drug Profile
    • sirolimus - Drug Profile
    • Small Molecules to Inhibit 5-Lipoxygenase for Uveitis - Drug Profile
    • Stem Cell Therapy for Autoimmune Diseases - Drug Profile
    • tesidolumab - Drug Profile
    • TOP-1288 - Drug Profile
    • triamcinolone acetonide - Drug Profile
  • Uveitis - Dormant Projects
  • Uveitis - Discontinued Products
  • Uveitis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Uveitis, H2 2016
  • Number of Products under Development for Uveitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Uveitis - Pipeline by 2-BBB Medicines BV, H2 2016
  • Uveitis - Pipeline by AbbVie Inc, H2 2016
  • Uveitis - Pipeline by Aciont Inc., H2 2016
  • Uveitis - Pipeline by Aldeyra Therapeutics Inc, H2 2016
  • Uveitis - Pipeline by Apitope International NV, H2 2016
  • Uveitis - Pipeline by Astellas Pharma Inc., H2 2016
  • Uveitis - Pipeline by Bionomics Limited, H2 2016
  • Uveitis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Uveitis - Pipeline by Can-Fite BioPharma Ltd., H2 2016
  • Uveitis - Pipeline by Clearside BioMedical, Inc., H2 2016
  • Uveitis - Pipeline by Endocyte, Inc., H2 2016
  • Uveitis - Pipeline by Enzo Biochem, Inc., H2 2016
  • Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016
  • Uveitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Uveitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Uveitis - Pipeline by Icon Bioscience, Inc., H2 2016
  • Uveitis - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Uveitis - Pipeline by Midatech Pharma Plc, H2 2016
  • Uveitis - Pipeline by Mitotech S.A., H2 2016
  • Uveitis - Pipeline by Neuroptis Biotech, H2 2016
  • Uveitis - Pipeline by Novartis AG, H2 2016
  • Uveitis - Pipeline by Oculis ehf, H2 2016
  • Uveitis - Pipeline by OncoNOx ApS, H2 2016
  • Uveitis - Pipeline by OSE Immunotherapeutics, H2 2016
  • Uveitis - Pipeline by Palatin Technologies, Inc., H2 2016
  • Uveitis - Pipeline by Panoptes Pharma Ges.m.b.H., H2 2016
  • Uveitis - Pipeline by Pfizer Inc., H2 2016
  • Uveitis - Pipeline by Precision Ocular Ltd, H2 2016
  • Uveitis - Pipeline by pSivida Corp., H2 2016
  • Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
  • Uveitis - Pipeline by SynDevRx, Inc., H2 2016
  • Uveitis - Pipeline by TopiVert Ltd, H2 2016
  • Uveitis - Pipeline by TxCell SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Uveitis - Dormant Projects, H2 2016
  • Uveitis - Dormant Projects (Contd..1), H2 2016
  • Uveitis - Dormant Projects (Contd..2), H2 2016
  • Uveitis - Dormant Projects (Contd..3), H2 2016
  • Uveitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Uveitis, H2 2016
  • Number of Products under Development for Uveitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top